Pharmacological inhibition of AKT not only improved the anti-tumor potential of Pmel CD8+ T cells and prolonged the survival of the mice but also rendered the Pmel CD8+ T cells responsive to anti-PD1 therapy (Fig. 6 F and G). Here, AKT1 is linked to neoplasm.